Pharmacokinetics and Imaging of ²¹² Pb-TCMC-Trastuzumab After Intraperitoneal Administration in Ovarian Cancer Patients

Abstract

Pharmacokinetics and imaging after 0.2 mCi/m2 IP 212Pb-TCMC-trastuzumab in patients with HER-2-expressing malignancy showed minimal distribution outside the peritoneal cavity, ≤6% urinary excretion, and good tolerance.